当前位置: X-MOL 学术Arch. Pharm. › 论文详情
Recent advances in isatin hybrids as potential anticancer agents
Archiv der Pharmazie ( IF 2.145 ) Pub Date : 2020-01-21 , DOI: 10.1002/ardp.201900367
Zhen Ding; Minfeng Zhou; Cheng Zeng

The isatin framework is a useful template for the development of novel anticancer agents. This is exemplified by the fact that several isatin‐based anticancer agents, such as semaxanib, sunitinib, nintedanib, and hesperadin, are already in use or under clinical trials for the treatment of diverse kinds of cancers. Isatin‐based hybrids could be obtained by incorporating other anticancer pharmacophores into the isatin skeleton and they have the potential to overcome drug resistance with reduced side effects. Thus, isatin‐based hybrids may provide attractive scaffolds for the development of novel anticancer agents. This review covers the recent advances of isatin‐based hybrids with anticancer activity, covering articles published between 2001 and 2019. The anticancer activities of these molecules and the structure–activity relationships are also discussed. The purpose of this review article is to set up the direction for the design and development of isatin‐based hybrids with high efficacy and low toxicity.
更新日期:2020-01-22

 

全部期刊列表>>
化学/材料学中国作者研究精选
ACS材料视界
南京大学
自然科研论文编辑服务
剑桥大学-
中国科学院大学化学科学学院
南开大学化学院周其林
课题组网站
X-MOL
北京大学分子工程苏南研究院
华东师范大学分子机器及功能材料
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug